Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial
In the multicenter VOLTAGE-2 trial, investigators will compare results of the company's tests with standard-of-care measures of drug response.
Personalis to Test MRD Assay in Triple-Negative Breast Cancer Trial With ABRCC, Criterium
The company has partnered with the Academic Breast Cancer Consortium and Criterium to assess its test in a prospective trial with five years of follow-up.
Foresight Diagnostics Closes $58.8M Series B Round
The Aurora, Colorado-based company plans to accelerate the clinical development and commercialization of its PhasED-seq MRD testing platform.
Personalis MRD Assays to Support UK's TRACERx ctDNA Monitoring Study
The ongoing lung cancer study, which has employed other assays in the past, will now use the Personalis NeXT Personal platform to monitor for recurrence after surgery.
Ambitions and timelines diverge, but innovators of expanded panels see broad testing as valuable to current patients and future precision oncology innovation.